Download PDF
Dtsch Med Wochenschr 2019; 144(11): 734-738
DOI: 10.1055/a-0663-6474
Klinischer Fortschritt
Kardiologie
© Georg Thieme Verlag KG Stuttgart · New York

Erkrankungen der Aorta: von der Aortenklappe bis zur Aortenbifurkation

Clinical Advances in Aortic Diseases: from Aortic Valve to Bifurcation
Christine Quast
1   Klinik für Kardiologie, Pneumologie und Angiologie, Universitätsklinikum Düsseldorf, Heinrich-Heine-Universität Düsseldorf
,
Sebastian Zimmer
2   Herzzentrum Bonn, Medizinische Klinik und Poliklinik II, Universitätsklinikum Bonn
,
Matti Adam
3   Klinik III für Innere Medizin – Allgemeine und interventionelle Kardiologie, Elektrophysiologie, Angiologie, Pneumologie und internistische Intensivmedizin, Uniklinik Köln
,
Stephan Baldus
3   Klinik III für Innere Medizin – Allgemeine und interventionelle Kardiologie, Elektrophysiologie, Angiologie, Pneumologie und internistische Intensivmedizin, Uniklinik Köln
,
Georg Nickenig
2   Herzzentrum Bonn, Medizinische Klinik und Poliklinik II, Universitätsklinikum Bonn
,
Malte Kelm
1   Klinik für Kardiologie, Pneumologie und Angiologie, Universitätsklinikum Düsseldorf, Heinrich-Heine-Universität Düsseldorf
4   CARID, Cardiovascular Research Institute Düsseldorf
› Author Affiliations
Further Information

Publication History

Publication Date:
04 June 2019 (online)

Also available at
   Permissions and Reprints

Was ist neu?

Stand der Dinge Sowohl im klinischen Bereich als auch in der Forschung etabliert sich zunehmend das Konzept, die Aorta als Gesamtorgan zu betrachten, das sich von der Aortenklappe bis zur Bifurkation erstreckt.

Aortenklappenstenose Aktuell laufen erste randomisierte Studien zur Ausweitung der Indikation zum interventionellen Aortenklappenersatz (TAVI, TAVR) hin zu einem Patientenkollektiv mit niedrigem OP-Risiko. Des Weiteren hat die interventionelle Versorgung der „Low flow, low gradient“-Aortenklappenstenose eine Aufwertung im Empfehlungsgrad erhalten und die interventionelle Valve-in-valve-Prozedur Eingang in den klinischen Alltag bei der individualisierten Patientenversorgung gefunden.

Aortenklappeninsuffizienz Kathetergestützt implantierte Klappenprothesen, die dediziert zur Behandlung der isolierten Aortenklappeninsuffizienz entwickelt werden, befinden sich für dieses Krankheitsbild in der klinischen Prüfung.

Erkrankungen der Aorta ascendens und descendens Während das Screening von Aortenaneurysmen zur ambulanten Routine wird, sind Studien zum risikostratifizierten Follow-up bei zunehmend endovaskulär versorgten Patienten notwendig, um eine bedarfsgerechte Nachsorge zu ermöglichen.

Abstract

There is growing understanding to recognize the aorta as complex system and treat aortic diseases in an integrated fashion.

The indication for interventional aortic valve replacement (TAVR) comprises patients with moderate and high perioperative risk and symptomatic, high grade aortic valve stenosis. In contrast „low risk“ patients receive conventional therapy. Ongoing randomised trials analyse the expansion of indication towards low risk patients for interventional approaches. A final rating is owing, but first data support the assumption that both therapeutic options may be equivalent. Moreover, the interventional therapy of low flow, low gradient aortic valve stenosis has been revalued and interventional valve-in-valve therapy has been integrated into clinical routine as invidualised decision of the heart team.

Aortic diseases include several entities which require specialised diagnostic and therapeutic tools. Studies to evaluate evidence of follow up options need to be performed in future to enable for surveillance tailored to suit medical need.

Schlüsselwörter

TAVI - Aortenklappenstenose - Aortenaneurysma - endovaskuläre Therapie - Follow-up

Key words

TAVR - aortic stenosis - aortic aneurysm - endovascular repair - follow up
 

  • Literatur

  • 1 Ribeiro HB, Lerakis S, Gilard M. et al. Transcatheter Aortic Valve Replacement in Patients With Low-Flow, Low-Gradient Aortic Stenosis: The TOPAS-TAVI Registry. J Am Coll Cardiol 2018; 71: 1297-1308
    CrossrefPubMedGoogle Scholar
  • 2 Baumgartner H, Falk V, Bax JJ. et al. 2017 ESC/EACTS Guidelines for the management of valvular heart disease. European Heart Journal 2017; 38: 2739-2791
    CrossrefPubMedGoogle Scholar
  • 3 Leon MB, Smith CR, Mack MJ. et al. Transcatheter or surgical aortic-valve replacement in intermediate-risk patients. N Engl J Med 2016; 374: 1609-1620
    CrossrefPubMedGoogle Scholar
  • 4 Rogers T, Torguson R, Bastian R. et al. Feasibility of transcatheter aortic valve replacement in low-risk patients with symptomatic severe aortic stenosis: Rationale and design of the Low Risk TAVR (LRT) study. Am Heart J 2017; 189: 103-109
    CrossrefPubMedGoogle Scholar
  • 5 Barker CM, Reardon MJ. Should TAVR Replace Surgery for Aortic Stenosis in Low- to Intermediate-Risk Patients?. Can J Cardiol 2017; 33: 1124-1128
    CrossrefPubMedGoogle Scholar
  • 6 Waksman R, Rogers T, Torguson R. et al. Transcatheter Aortic Valve Replacement in Low-Risk Patients With Symptomatic Severe Aortic Stenosis. J Am Coll Cardiol 2018; 72: 2095-2105
    CrossrefPubMedGoogle Scholar
  • 7 Bekeredjian R, Szabo G, Balaban Ü. et al. Patients at low surgical risk as defined by the Society of Thoracic Surgeons Score undergoing isolated interventional or surgical aortic valve implantation: in-hospital data and 1-year results from the German Aortic Valve Registry (GARY). Eur Heart J 2018; DOI: 10.1093/eurheartj/ehy699.
    CrossrefPubMedGoogle Scholar
  • 8 Serruys PW, Modolo R, Reardon M. et al. One-year outcomes of patients with severe aortic stenosis and an STS PROM of less than three percent in the SURTAVI trial. EuroIntervention 2018; 14: 877-883
    CrossrefPubMedGoogle Scholar
  • 9 Bagur R. Transcatheter aortic valve looking for low-risk patients: a post hoc analysis of SURTAVI keeps opening the door. EuroIntervention 2018; 14: 846-848
    CrossrefPubMedGoogle Scholar
  • 10 Søndergaard L, Steinbrüchel DA, Ihlemann N. et al. Two-Year Outcomes in Patients With Severe Aortic Valve Stenosis Randomized to Transcatheter Versus Surgical Aortic Valve Replacement: The All-Comers Nordic Aortic Valve Intervention Randomized Clinical Trial. Circ Cardiovasc Interv 2016; 9: e003665
    PubMedGoogle Scholar
  • 11 Manoharan G, Van Mieghem NM, Windecker S. et al. 1-Year Outcomes With the Evolut R Self-Expanding Transcatheter Aortic Valve: From the International FORWARD Study. JACC Cardiovasc Interv 2018; 11: 2326-2334
    CrossrefPubMedGoogle Scholar
  • 12 Hellhammer K, Piayda K, Afzal S. et al. The Latest Evolution of the Medtronic CoreValve System in the Era of Transcatheter Aortic Valve Replacement: Matched Comparison of the Evolut PRO and Evolut R. JACC Cardiovasc Interv 2018; 11: 2314-2322
    CrossrefPubMedGoogle Scholar
  • 13 Jilaihawi H, Williams M. Surgical Versus First-Generation Self-Expanding Transcatheter Aortic Valve Replacement: Is TAVR More Durable?. J Am Coll Cardiol 2018; 72: 2697-2700
    CrossrefPubMedGoogle Scholar
  • 14 Erbel R, Aboyans V, Boileau C. et al. 2014 ESC Guidelines on the diagnosis and treatment of aortic diseases: Document covering acute and chronic aortic diseases of the thoracic and abdominal aorta of the adult. The Task Force for the Diagnosis and Treatment of Aortic Diseases of the European Society of Cardiology (ESC). Eur Heart J 2014; 35: 2873-2926
    CrossrefPubMedGoogle Scholar
  • 15 Erbel R, Eggebrecht H, Falk V. et al. Kommentar zur 2014-Leitlinie der Europäischen Gesellschaft für Kardiologie (ESC) zur Diagnose und Therapie von Aortenerkrankungen. Kardiologe 2015; 9: 348-353
    CrossrefPubMedGoogle Scholar
  • 16 Takagi H, Goto SN, Matsui M. et al. A further meta-analysis of population based screening for abdominal aortic aneurysm. J Vasc Surg 2010; 52: 1103-1108
    CrossrefPubMedGoogle Scholar
  • 17 Goncalves FB. Post-EVAR Surveillance Considerations, Evaluating and stratifying risks based on currently available data. Endovascular today 2017; 16: 90-92
    PubMedGoogle Scholar